The Icahn School of Medicine at Mount Sinai has developed a “genetic priority score” (GPS) to transform the prioritization process in drug development. Published in Nature Genetics, this novel tool amalgamates various types of human genetic data into a single, comprehensive score. This tool combines eight genetic features and drug indication information from the Open Targets and SIDER databases. It is designed to enhance the likelihood of success in clinical trials by focusing on genes with strong genetic support, thereby identifying established and potential novel drug targets.
The Right Loves Genetic Goo more than Babies and Actual People
The Alabama Supreme Court decided this week that frozen embryos are fully fledged human beings, entitled to the rights and protections that entails. Specifically,…